Andy Shah

Andy Shah of William Blair inquired about the degree of overlap between the clinical trial sites used for the MASH and obesity programs and the sites planned for the upcoming AUD and ALD trials.

Answer

An Altimmune executive stated that while there is 'some overlap' between the site networks due to the commonality of obesity in these patient populations, he could not provide specific data on the percentage of overlapping sites at this time.

Andy Shay asked about the ADC modality, specifically what learnings from the XB002 program are being applied to XB371 and whether the two ADCs share the same antibody component.

Answer

Chief Scientific Officer Dana Aftab confirmed that XB371 uses the same anti-tissue factor antibody as XB002 but features a different payload (a topoisomerase inhibitor). He highlighted the antibody's differentiated epitope, which avoids blood clotting issues, and the strategic value of advancing an ADC in colorectal cancer to build upon the company's GI franchise.

Andy Shah asked about the scientific validation for switching the pancreatic cancer trial to a NALIRIFOX combination, particularly regarding drug synergy, and inquired if the company is exploring preclinical combinations of onvansertib with antibody-drug conjugates (ADCs) for ovarian cancer.

Answer

Executive Mark Erlander stated that the known synergy between onvansertib and irinotecan (a key component of NALIRIFOX) was a primary driver for the change in the pancreatic cancer trial. He also noted the lead investigator's prior positive experience with the drug. Regarding the pipeline, Erlander confirmed that Cardiff Oncology is actively conducting preclinical work combining onvansertib with ADCs, not only for ovarian cancer but for other indications as well.